Navigation Links
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Date:3/11/2009

uses hemolytic anemia. The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen.

Contraindications

PEGINTRON is contraindicated in patients with known hypersensitivity reactions such as urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens Johnson syndrome and toxic epidermal necrolysis to interferon alpha or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in cirrhotic CHC patients before or during treatment. PEGINTRON/REBETOL combination therapy is additionally contraindicated in women who are pregnant or may become pregnant (see Boxed Warning and Pregnancy section), men whose female partners are pregnant, patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia), and patients with creatinine clearance less than 50 mL per min.

Pregnancy

REBETOL therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients during therapy and 6 months post-treatment. Patients should use at least two effective forms of contraception and have monthly pregnancy tests during therapy and for 6 months after completion of therapy. If this drug is used during pregnancy or if a patient becomes pregnant, the patient should be apprised of the potential hazard to a fetus. A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for 6 months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

Incid
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... SINGAPORE, Dec. 15 ... that it has completed the previously announced ... manufacturer of disposable medical devices ranging from ... surgery. Through its medical segment, Flextronics provides ... device, medical equipment, and pharmaceutical customers. Terms ...
(Date:12/15/2009)... WASHINGTON, Dec. 15 Today,s ... Sack, "Plan for Kidney Drugs Spurs Division," illustrates ... result in kidney patients continuing to be deprived ... 36-month Medicare program limit. ,, As Congress is ... to preserve the lives of transplant kidney recipients, ...
(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... Analysis and Market Forecasts to 2015 ... ,, Systemic Lupus Erythematosus - Drug ... 2015 ,, Summary ,, ...
Breaking Medicine Technology:Flextronics Completes SloMedical Acquisition 2AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate 2Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 2Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 3Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 4Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 5Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 6Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 7Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 8RAM Technologies Named to Philadelphia Business Journals List of Top Tech Employers 58994 1RAM Technologies Named to Philadelphia Business Journals List of Top Tech Employers 58994 2Amnis Begins Shipment of New ImageStreamX Imaging Flow Cytometers 5275 1Amnis Begins Shipment of New ImageStreamX Imaging Flow Cytometers 5275 2Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350 5272 1Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350 5272 2
... 29 Sanofi-aventis,announced today that the U.S. Food ... origin] injection) to improve glycemic,control in children (4 ... approval of Apidra(R) for pediatric use is based ... active control study of Apidra(R) in,comparison with insulin ...
... results to be presented at 2008 ICAAC/IDSA ... Sequella, Inc., a,clinical-stage biopharmaceutical company focused ... epidemic potential, announces the,successful demonstration of synergistic ... resulting from in vitro combination,studies of Sequella ...
Other Medicine Technology:FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 2FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 3FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 4FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 5Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207 2
(Date:12/15/2009)... Dec. 15 The new compact LifeSpan TR200 ... www.LifeSpanFitness.com ), was highly praised by treadmill ... for 2010. The compact TR200 folding treadmill received awards ... Treadmill under $1000. ,, The compact LifeSpan TR200 ... small workout spaces. "This category buster is a very ...
(Date:12/15/2009)... ARBOR, Mich. A new study links chronic obstructive ... that act as sentinels to activate the body,s immune ... Affairs research adds to growing awareness of the immune ... that affects more than 12 million Americans with wheezing, ... immune factors is key if doctors are to find ...
(Date:12/15/2009)... developmental changes increases risk in teens, study suggests , , ... overweight or obese increases the risk of obstructive sleep ... true for younger children, Australian researchers have found. , ... 2 to 18, who were referred for evaluation of ... that among those aged 12 and older the risk ...
(Date:12/15/2009)... for injury when doctors decide benefits of imaging outweigh ... MRI scans can pose a serious risk to people ... Drug Administration researchers exposed pacemakers to a simulated MRI ... at the tip of the pacemaker lead, where it ... The exposure to MRI magnetic pulses caused certain pacemakers ...
(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... the U.S. and its International Trade ... http://www.reportlinker.com/p0167482/In-Vitro-Diagnostic-Substance-Manufacturing-Industry-in-the-US-and-its-International-Trade-[Q4-2009-Edition].html ,, The newly published ... provides the latest market research on ...
Breaking Medicine News(10 mins):Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2Health News:Immune cell activity linked to worsening COPD 2Health News:Immune cell activity linked to worsening COPD 3Health News:Puberty May Trigger Sleep Apnea in Overweight Kids 2Health News:Patients With Pacemakers Should Avoid MRI Scans 2Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 2Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 3Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 4Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 5Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 6Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 7Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 8
... WASHINGTON, March 13 A former Department of Veterans ... a jury on four counts of honest services mail ... making a false statement to agency officials, Acting Assistant ... E. Nahmias of the Northern District of Georgia announced. ...
... , "Listen to caregivers and be willing to collaborate ... can either master it or it can master you."ALEXANDRIA, ... the cusp of massive health care reform, the American ... to leading the charge to control costs, improve quality, ...
... new Rice University report released yesterday, exactly six months ... that people did not practice the lessons learned from ... of Harris County residents say they would evacuate if ... significant potential increase over the 24 percent of residents ...
... is more difficult to recognize and treat epilepsy in ... of Deutsches rzteblatt International ( Dtsch Arztebl ... the Epilepsy Center of Johannes Gutenberg University in Mainz, ... the therapeutic options. , It is often not ...
... EXTON, Pa., March 13 Kensey Nash Corporation (Nasdaq: ... the Sidoti Thirteenth Annual New York Emerging Growth Institutional ... City on Tuesday, March 24, 2009.Joseph W. Kaufmann, Kensey ... approximately 11:35 a.m. (ET). The presentation materials will ...
... Calif., March 13 Transcept Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of proprietary products that address ... announced it will report results for its fourth quarter ... A conference call to review the results will begin ...
Other Medicine News:Health News:Jury Convicts Former Social Worker of Defrauding The Department of Veterans Affairs and Obstructing Justice 2Health News:APTA's Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change 2Health News:APTA's Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change 3Health News:APTA's Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change 4Health News:Rice report shows lessons from Hurricane Rita not practiced during Ike 2Health News:Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results 2Health News:Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: